TrovaGene Inc.
Form 8-K
December 21, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 20, 2012**

Trovagene, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**27-2004382**
(State or other jurisdiction	IRS Employer
of incorporation or organization)	Identification No.)

11055 Flintkote Avenue, Suite B

San Diego, CA 92121

(Address of principal executive offices)

Registrant s telephone number, including area code: **(858) 217-4838**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01   **Other Events.**

On December 20, 2012, Trovagene, Inc. (the   Company) issued a press release announcing the granting of a worldwide, non-exclusive license to incorporate nucleophosmin protein, NPM1, into research and clinical testing services for acute myelogenous leukemia to Genoptix, Inc. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01   **Financial Statements and Exhibits**

(d)   Exhibits.

99.1   Press Release dated December 20, 2012

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 21, 2012

TROVAGENE, INC.

By: /s/ Antonius Schuh
                             Antonius Schuh
                             Chief Executive Officer

3